Literature DB >> 24141441

Suboccipital craniectomy with opening of the fourth ventricle and duraplasty: study of 192 cases of craniovertebral malformations.

José Alberto Gonçalves da Silva1, Adailton Arcanjo dos Santos, Maria do Desterro Leiros da Costa, Everardo Bandeira de Almeida.   

Abstract

The prime objective in the surgical treatment of basilar impression (BI), Chiari malformation (CM), and/or syringomyelia (SM) is based on restoration of the normal cerebrospinal fluid (CSF) dynamics at the craniovertebral junction and creation of a large artificial cisterna magna, avoiding the caudal migration of the hindbrain. It is observed that a large craniectomy might facilitate an upward migration of the posterior fossa structures. There are many surgical techniques to decompress the posterior fossa; however, a gold standard approach remains unclear. The authors present the results of 192 cases of BI, CM, and SM treated between 1975 and 2008 and whose surgical treatment was characterized by a large craniectomy without tonsillectomy with the patient in the sitting position, large opening of the fourth ventricle, and duraplasty.

Entities:  

Mesh:

Year:  2013        PMID: 24141441     DOI: 10.1590/0004-282X20130105

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  2 in total

Review 1.  The effect of posterior fossa decompression in adult Chiari malformation and basilar invagination: a systematic review and meta-analysis.

Authors:  Ulysses de Oliveira Sousa; Matheus Fernandes de Oliveira; Lindolfo Carlos Heringer; Alécio Cristino Evangelista Santos Barcelos; Ricardo Vieira Botelho
Journal:  Neurosurg Rev       Date:  2017-05-02       Impact factor: 3.042

Review 2.  Basilar invagination associated with chiari malformation type I: A literature review.

Authors:  José Nazareno Pearce de Oliveira Brito; Bruna Afonso Dos Santos; Isys Fialho Nascimento; Leonardo Augusto Martins; Cléciton Braga Tavares
Journal:  Clinics (Sao Paulo)       Date:  2019-04-08       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.